Luz A Moreno-Quispe1,2, Julia Serrano3, Leire Virto4, Mariano Sanz1, Lucía Ramírez3, Mónica Fernández-Castro5, Gonzalo Hernández3, Rosa María López-Pintor3. 1. Department of Dental Clinical Specialties, School of Dentistry, Complutense University, Madrid, Spain. 2. Universidad Nacional de Frontera, Piura, Peru. 3. Department of Dental Clinical Specialties, ORALMED Research Group, School of Dentistry, Complutense University, Madrid, Spain. 4. Researcher, Etiology and Therapy of Periodontal Diseases (ETEP) Research Group, Complutense University and Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. 5. Rheumatology Service, Hospital Puerta de Hierro, Madrid, Spain.
Abstract
BACKGROUND: Primary Sjogren's syndrome (pSS) is an autoimmune disease that leads to salivary and lacrimal gland dysfunction. The adaptive immune response associated with T helper-2 lymphocytes appears to be altered in these patients. Therefore, the objective of this study was to determine the salivary levels of interleukin (IL)-6, IL-5, and IL-4 in patients with pSS when compared to a healthy control (HC) group. The secondary objectives were to study whether ILs levels in pSS patients were associated with salivary flow, patient-reported outcomes (PROMs) for xerostomia and oral health quality of life (Oral Health Impact Profile-14 [OHIP-14]), pSS classification criteria and presence of extraglandular manifestations. METHODS: A case-control study was conducted in 36 patients with pSS and 35 HCs. Cytokine levels were measured using high-sensitivity multiplex map human immunoassays. Unstimulated and stimulated whole saliva were collected and patients filled out questionnaires. The Mann-Whitney U test, chi-squared test, and Spearman correlation test were used. RESULTS: Interleukin-6 was significantly higher in pSS patients than in HCs (P = .0001). IL-6 was significantly higher in pSS patients with a positive salivary gland biopsy (P = .04), whole stimulated saliva hyposalivation (P = .02), and presence of musculoskeletal disorders (P = .03). There was a non-significant positive correlation between IL-6 levels and PROMs for xerostomia (r = .31; P = .06) and OHIP-14 (r = .07; P = .68) in pSS patients. Levels of IL-4 and IL-5 were not detected in both pSS and HCs patients. CONCLUSIONS: Salivary IL-6 levels are significantly associated with pSS patients, and therefore, it is hypothesized that this biomarker may be useful in the diagnosis and follow-up of this disease.
BACKGROUND:Primary Sjogren's syndrome (pSS) is an autoimmune disease that leads to salivary and lacrimal gland dysfunction. The adaptive immune response associated with T helper-2 lymphocytes appears to be altered in these patients. Therefore, the objective of this study was to determine the salivary levels of interleukin (IL)-6, IL-5, and IL-4 in patients with pSS when compared to a healthy control (HC) group. The secondary objectives were to study whether ILs levels in pSSpatients were associated with salivary flow, patient-reported outcomes (PROMs) for xerostomia and oral health quality of life (Oral Health Impact Profile-14 [OHIP-14]), pSS classification criteria and presence of extraglandular manifestations. METHODS: A case-control study was conducted in 36 patients with pSS and 35 HCs. Cytokine levels were measured using high-sensitivity multiplex map human immunoassays. Unstimulated and stimulated whole saliva were collected and patients filled out questionnaires. The Mann-Whitney U test, chi-squared test, and Spearman correlation test were used. RESULTS: Interleukin-6 was significantly higher in pSSpatients than in HCs (P = .0001). IL-6 was significantly higher in pSSpatients with a positive salivary gland biopsy (P = .04), whole stimulated saliva hyposalivation (P = .02), and presence of musculoskeletal disorders (P = .03). There was a non-significant positive correlation between IL-6 levels and PROMs for xerostomia (r = .31; P = .06) and OHIP-14 (r = .07; P = .68) in pSSpatients. Levels of IL-4 and IL-5 were not detected in both pSS and HCs patients. CONCLUSIONS: Salivary IL-6 levels are significantly associated with pSSpatients, and therefore, it is hypothesized that this biomarker may be useful in the diagnosis and follow-up of this disease.
Authors: H T Dos Santos; K Nam; C T Brown; S M Dean; S Lewis; C S Pfeifer; P Lei; M J Petris; S T Andreadis; O J Baker Journal: J Dent Res Date: 2020-10-10 Impact factor: 6.116
Authors: Andrea Cruz; Maria Vieira; Ana R Mesquita; Adriana Sampaio; Inês Mendes-Pinto; Isabel Soares; Paulo P Freitas Journal: Front Neurosci Date: 2022-09-26 Impact factor: 5.152
Authors: K Morawska; M Maciejczyk; S Zięba; Ł Popławski; A Kita-Popławska; J Krętowski; A Zalewska Journal: Mediators Inflamm Date: 2021-07-11 Impact factor: 4.711